Bots, editor, reviewer, Administrators
13,941
edits
WikiJournalClub:High-priority articles: Difference between revisions
Jump to navigation
Jump to search
WikiJournalClub:High-priority articles (view source)
Revision as of 21:15, 23 November 2024
, 23 November 2024STEP-HFpEF now reviewable
(PREVAIL complte) |
(STEP-HFpEF now reviewable) |
||
| Line 5: | Line 5: | ||
<div id="wjc-articles"> | <div id="wjc-articles"> | ||
===Reviewable=== | ===Reviewable=== | ||
* 2023 {{create article link|STEP-HFpEF}}: GLP-1 agonist in HFpEF and obesity [https://www.nejm.org/doi/full/10.1056/NEJMoa2306963] | |||
===Incomplete or nonexistent=== | ===Incomplete or nonexistent=== | ||
* 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | * 2024 {{create article link|REVIVE}}: Rusfertide vs. placebo in PV [https://www.nejm.org/doi/full/10.1056/NEJMoa2308809] | ||
* 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | * 2023 {{create article link|Thalidomide for small intestine angiodysplasia}}: Thalidomide in angiodysplasia of the small intestine [https://www.nejm.org/doi/full/10.1056/NEJMoa2303706] | ||
* 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | * 2023 {{create article link|ENLIVEN}}: FGF21 analogue in NASH [https://www.nejm.org/doi/full/10.1056/NEJMoa2304286] | ||
* 2023 {{create article link|Clarity AD}}: Lecanemab in Alzheimer's disease [https://www.nejm.org/doi/full/10.1056/NEJMoa2212948] | * 2023 {{create article link|Clarity AD}}: Lecanemab in Alzheimer's disease [https://www.nejm.org/doi/full/10.1056/NEJMoa2212948] | ||